Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma
Status:
Active, not recruiting
Trial end date:
2022-05-19
Target enrollment:
Participant gender:
Summary
This is a multi-center, prospective, single-arm phase I/Ib safety trial. Patients eligible
for treatment must be diagnosed with non-metastatic, biopsy-proven stage II-IVB oral cavity,
stage III-IVB larynx and hypopharynx, or stage III-IVB HPV/p16 negative intermediate-high
risk oropharynx head and neck cancer, and must be eligible and amenable to surgical
resection.